Azithromycin to Prevent Wheezing Following Severe RSV Bronchiolitis-II
The main objective of the APW-RSV II clinical trial is to evaluate if the addition of azithromycin to routine bronchiolitis care, among infants hospitalized with RSV bronchiolitis, reduces the occurrence of recurrent wheeze during the preschool years.
• Age: 1-18 months.
• Hospitalization for the first episode of RSV bronchiolitis.
• Confirmed RSV infection by positive nasal swab results (PCR assay and/or direct antigen detection).
• At least two of the following symptoms/signs of bronchiolitis: respiratory rate greater than 40 breaths/minute; cough; wheezing; audible rales, crackles, and/or rhonchi; paradoxical chest movements (retractions)28.
• Duration of respiratory symptoms from onset of symptoms of the current illness to admission is 120 hours (5 days) or less.
• Randomization can be performed within 168 hours (7 days) from onset of symptoms.
• Willingness to provide informed consent by the child's parent or guardian.